Guidance on the licensing of biosimilar products

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued comprehensive guidance for developers seeking to license biosimilar medicinal products within the United Kingdom, specifically covering Northern Ireland and Great Britain. As this is a general regulatory framework document rather than an enforcement notice, it does not name a specific company or list inspection dates and violations. Instead, the framework establishes the mandatory standards for the development and approval of similar biological products. The regulatory framework requires applicants to adhere to both MHRA-specific updates and the established principles of the Committee for Medicinal Products for Human Use (CHMP). This guidance incorporates scientific and regulatory insights gained since the first biosimilar approval in 2006, with specific revisions addressing complex products like monoclonal antibodies and fusion proteins. To comply, developers must follow these clarified licensing pathways to ensure their products meet safety and efficacy standards. The MHRA specifies that these requirements are strictly for biosimilars; applicants dealing with advanced therapy medicinal products (ATMPs), plasma master files, or vaccine antigen master files must follow separate, specialized regulatory tracks. This guidance ensures that biosimilar development in the UK remains aligned with international scientific advancements while providing clear procedural steps for manufacturers.